Take Solutions reported disappointing set of numbers in Q3FY19, with EBITDA and profits declining significantly on a year-on-year (YoY) basis. Talking about the numbers and future outlook, VC & MD, Take Solutions, Srinivasan HR said that in FY20, organic revenue growth should be 16-17 percent, and with the two acquisitions done in Q3, the company should drive around 28-29 percent growth.
Discussing about the weak margins in the third quarter, he said they were impacted by two events, one was the acquisition expense of $1.8 million of two US companies, and the other one was on account of foreign exchange loss.
On the clinical vertical business of the company, he said, "Currently it is around 40 percent of total revenues and year-to-date (YTD), it is around 36 percent. Going forward, over the next two years, this vertical would be around 60-65 percent of the total revenues."
"The margins on the clinical business are around 18-19 percent and that on regulatory and safety are higher. However, clinical segment is a bulkier business with long-tenure contracts, while the regulatory and safety business arises out of the clinical business", he said. Moreover, the spending on R&D pharma on clinical is the largest.